Video

Examining LIFU-Aided Liquid Biopsy in Glioblastoma: Key Objectives of the LIBERATE Trial

In this third episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the LIBERATE study (NCT05383872) examining low-intensity focused ultrasound in patients with glioblastoma.

In this third episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, both of Baptist Health South Florida, discuss the LIBERATE study (NCT05383872) examining low-intensity focused ultrasound (LIFU) in patients with glioblastoma.

Ahluwalia: Thank you for sharing that, Mike. The first patient that [Dr McDermott] treated in the state of Florida was part of a bigger trial called LIBERATE; this is an FDA approval study [that will include] up to 50 patients who will [receive] LIFU. The intent of that trial is to see at least a two-fold increase in the circulating [tumor] DNA [ctDNA] of patients with glioblastoma, whether they are newly diagnosed or [have] recurrent [disease].

[In this] study, [we are looking] at the level of ctDNA in these patients before the procedure is done. Then, after the procedure is performed, we [will] collect blood at 30 minutes, an hour, and a couple hours after that. The FDA approval discussion [established that the trial would be successful] if [we observe] a two-fold increase in the level of ctDNA, and there is more than 75% concordance between what we find in terms of genomics of ctDNA that matches up with the surgery that neurosurgeons like Dr McDermott will do for patients [when] clinically indicated.

The trial is ongoing at multiple sites in North America, including Miami Cancer Institute, Mayo Clinic, and NYU [Langone]. The study is also open at University of Maryland, [as well as] a site in Toronto at Sunnybrook [Research Institute]. Numerous other sites are in the process of opening it.

Check back next Tuesday for the next episode in the series.

Related Videos
Marc Machaalani, MD
Seema Nagpal, MD
Marco Davila, MD, PhD
Danielle E. Hammond, MD, FRCP(C)
Salman R. Punekar, MD
Thomas Marron, MD, PhD
A Phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent high-grade glioma (HGG) patients with EGFR alterations or fusions
Video 8 - 2 KOLs featured in , "Q&A: Final Questions on Glioblastoma and Neuroimaging"
Video 7 - 2 KOLs featured in, "Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment "
Rohan Garje, MD